# DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes

Study · id `cardio:ct-nct07241897` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07241897](<https://clinicaltrials.gov/study/NCT07241897>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07241897

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 312 participants.

## Technical summary

Registry record NCT07241897. Randomized; triple masking; primary purpose treatment. Start 2025-12-15 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 312 participants (planned count; ClinicalTrials.gov record NCT07241897, source copy `cardio:ctgov-nct07241897-2025-11-21`, retrieved 2026-10-26)
- Planned start: 2025-12-15 (anticipated) (ClinicalTrials.gov record NCT07241897, source copy `cardio:ctgov-nct07241897-2025-11-21`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07241897, source copy `cardio:ctgov-nct07241897-2025-11-21`, retrieved 2026-10-26)
- Completion: 2028-04-30 (anticipated) (ClinicalTrials.gov record NCT07241897, source copy `cardio:ctgov-nct07241897-2025-11-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07241897, source copy `cardio:ctgov-nct07241897-2025-11-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07241897-2025-11-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes
- Condition: Ischemic Stroke
- Condition: Diabete Mellitus
- Intervention (Drug): Sentagliptin Phosphate - single dose
- Intervention (Drug): Placebo
- Lead sponsor: Second Affiliated Hospital of Soochow University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital of Soochow University (`cardio:org-second-affiliated-hospital-of-soochow-university`)

## Provenance

Content hash: 46b4a49c9735f8bb2a282e75ebe30f2a4d2523a035db163e11c8f8e9cf7516c8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
